Xarelto (rivaroxaban)

Drug Class

Factor Xa inhibitor

Indication for Use



Uncontrolled internal bleed events
Intracranial hemorrhage


Xarelto (rivaroxaban) is a Factor Xa Inhibitor, or anticoagulant, approved in 2011 for the prevention of blood clots that can lead to injuries such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Xarelto is the second most prescribed drug for lowering the risk of stroke in patients with atrial fibrillation.

Manufacturer Janssen Pharmaceuticals, Inc. aggressively marketed Xarelto as the convenient alternative to other similar medications because it required no routine blood testing or monitoring. Xarelto’s high degree of variability, when left unchecked, creates a dangerous situation wherein the blood may become too thin, leading to uncontrolled bleed events. These events cause serious health risks and complications, and in some cases, can lead to death.

Multi District Litigation (MDL) number 2592 was formed in United States Eastern District of Louisiana the before the Honorable Judge Eldon E. Fallon, and several claims have been filed, with many more anticipated to follow both there and throughout the country.